SCHEMBL4264187

SCHEMBL4264187

Cc1cc(-c2csc(-c3cccnc3)n2)cc2c1OCC(=O)N2

nearest known ligand 0.53

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP19A1 P11511 9/20 0.53
AXL P30530 1/20 0.53
PBRM1 Q86U86 1/20 0.53
MKNK1 Q9BUB5 1/20 0.53
MKNK2 Q9HBH9 1/20 0.53
RAB9A P51151 6/20 0.51
NPC1 O15118 5/20 0.51
MAPT P10636 4/20 0.51
KDM4E B2RXH2 3/20 0.51
LMNA P02545 2/20 0.51
NPSR1 Q6W5P4 1/20 0.51
L3MBTL1 Q9Y468 1/20 0.51
ALDH1A1 P00352 2/20 0.50
MAPK1 P28482 2/20 0.50
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
SMN1; SMN2 Q16637 1/20 0.50
POLB P06746 2/20 0.49
TP53 P04637 1/20 0.49
CYP17A1 P05093 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4264617 0.97 CYP19A1 (0.53) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL4258310 0.89 CYP19A1 (0.54) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL4267804 0.89 POLB (0.55) CYP19A1RAB9ANPC1MAPTKDM4E
SCHEMBL4260706 0.88 RAB9A (0.55) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL4269384 0.87 POLB (0.52) CYP19A1RAB9ANPC1MAPTKDM4E
SCHEMBL4261462 0.86 CYP19A1 (0.50) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL4264246 0.85 RAB9A (0.54) CYP19A1AXLPBRM1MKNK1MKNK2
SCHEMBL4259481 0.84 ALDH1A1 (0.55) CYP19A1RAB9ANPC1MAPTKDM4E
SCHEMBL4264625 0.84 ALDH1A1 (0.55) CYP19A1RAB9ANPC1MAPTKDM4E
SCHEMBL4259514 0.83 POLB (0.50) RAB9ANPC1MAPTKDM4ELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US claimed
JP-2008508314-A 2008-03-21 JP claimed
EP-1778242-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2007-05-02 EP claimed
WO-2006015259-A2 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2006-02-09 WO claimed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS IRM LLC (BM) 2009-02-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090054417-A1 COMPOUNDS AND COMPOSITIONS AS MODULATORS OF STEROID HORMONE NUCLEAR RECEPTORS NR5A1, ESRRA, NR3C1 CYP19A1 54/4885AXL 4021/4885PBRM1 2031/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.